← Back to Home

Disrupting Brain Cancer’s Repair Defenses: SET Protein Emerges as a New Target in Glioblastoma Research

Restoring PP2A activity suppressed by cancer cells may weaken tumors’ ability to grow and resist radiation. Cell and mouse experiments offer clues, but key questions remain before a safe and effective treatment for humans can be developed.

By SURL BioNews

Glioblastoma is difficult to treat partly because cancer cells can adjust growth signals and activate repair mechanisms after treatment causes damage. A team at The Ohio State University in the United States has identified a potential way to weaken these defenses: lifting cancer cells’ suppression of a regulatory enzyme, allowing it to limit tumor growth again while making cancer cells less able to withstand radiation damage.

The study was published online on February 20, 2026, and appeared in the May 1 issue of *Cancer Letters*. It was subsequently covered in university news and on science news websites in August and September. The research focused on protein phosphatase 2A (PP2A), which removes phosphate groups from proteins and helps regulate cell signaling. The team found that glioblastoma increases the expression of three endogenous inhibitory proteins—ANP32A, CIP2A, and SET—suppressing PP2A’s regulatory function.

After using CRISPR-Cas9 to inactivate these inhibitory proteins, the researchers observed restored PP2A activity and disruption of signals that promote cancer cell growth. The effect of targeting SET was particularly pronounced. According to the university’s account, inhibiting SET prevented tumor formation in the preclinical models tested, making it a priority target for the team’s further investigation.

Another effect relates to radiation therapy. Radiation damages DNA, while cancer cells can use kinases such as ATM and ATR to coordinate repair and pause the cell cycle, creating an opportunity to survive. The study showed that removing PP2A’s inhibitory proteins enabled PP2A to act more effectively on these kinases, disrupting DNA repair and cell cycle checkpoints and increasing cancer cells’ sensitivity to radiation.

However, preventing genetically manipulated cancer cells from forming tumors in models and using drugs to treat established tumors in patients remain different challenges. These results support further investigation of the PP2A regulatory pathway, but do not yet demonstrate that inhibiting SET can shrink patients’ tumors, extend survival, or improve chemotherapy outcomes.

The university also noted that the team tested an antipsychotic drug already approved by the U.S. Food and Drug Administration that can increase PP2A activity. This offers a lead for drug research, but approval for its existing indication does not mean it is suitable for brain cancer. The university explicitly stated that it should not currently be used to treat glioblastoma outside clinical trials.

The key questions ahead are whether SET or related inhibitory proteins can be targeted safely, and whether the radiation-sensitizing effects seen in models can translate into benefits for patients. This pathway provides a mechanistic basis for improving existing treatments, but both efficacy and safety still require testing in human studies.

References

  1. ScienceDaily Top Health
  2. Cancer Letters via PubMed
  3. Medical Xpress / Ohio State University Medical Center